Journal article
Therapeutic effects of CuII(atsm) in the SOD1-G37R mouse model of amyotrophic lateral sclerosis
EJ McAllum, NKH Lim, JL Hickey, BM Paterson, PS Donnelly, QX Li, JR Liddell, KJ Barnham, AR White, PJ Crouch
Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration | TAYLOR & FRANCIS LTD | Published : 2013
Abstract
Our objective was to assess the copperII complex of diacetylbis(4-methylthiosemicarbazone) [CuII(atsm)] for its preclinical potential as a novel therapeutic for ALS. Experimental paradigms used were designed to assess CuII(atsm) efficacy relative to treatment with riluzole, as a function of dose administered, and when administered post symptom onset. Mice expressing human Cu/Zn superoxide dismutase harbouring the disease-causing G37R mutation (SOD1-G37R) were used and effects of CuII(atsm) determined by assessing mouse survival and locomotor function (rotarod assay). CuII(atsm) improved SOD1-G37R mouse survival and locomotor function in a dose-dependent manner. The highest dose tested improv..
View full abstractRelated Projects (2)
Grants
Awarded by Motor Neurone Disease Research Institute of Australia
Funding Acknowledgements
This work was supported by the Australian National Health and Medical Research Council (NHMRC) Project Grant 1005651, The University of Melbourne, The Motor Neurone Disease Research Institute of Australia, and the Australian Research Council (ARC). None of these funding bodies contributed to study design, the collection, analysis and interpretation of data, writing the report, or the decision to submit the article for publication.